Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme

Sergei M. Danilov*, Jean M. Watermeyer, Irina V. Balyasnikova, Kerry Gordon, Elena V. Kugaevskaya, Yulia E. Elisseeva, Ronald F. Albrecht, Edward D. Sturrock

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Angiotensin I-converting enzyme (ACE, peptidyl dipeptidase, EC 3.4.15.2) is a key enzyme in cardiovascular pathophysiology. A wide spectrum of monoclonal antibodies to different epitopes on the N and C domains of human ACE has been used to study different aspects of ACE biology. In this study we characterized the monoclonal antibody (mAb) 5F1, developed against the N domain of human ACE, which recognizes both the catalytically active and the denatured forms of ACE. The epitope for mAb 5F1 was defined using species cross-reactivity, synthetic peptide (PepScan technology) and phage display library screening, Western blotting, site-directed mutagenesis, and protein modeling. The epitope for mAb 5F1 shows no overlap with the epitopes of seven other mAbs to the N domain described previously and is localized on the other side of the N domain globule. The binding of mAb 5F1 to ACE is carbohydrate-dependent and increased significantly as a result of altered glycosylation after treatment with α-glucosidase-1 inhibitor, N-butyldeoxynojirimycin (NB-DNJ), or neuraminidase. Out of 17 species tested, mAb 5F1 showed strict primate ACE specificity. In addition, mAb 5F1 recognized human ACE in Western blots and on paraffin-embedded sections. The sequential part of the epitope for mAb 5F1 is created by the N-terminal part of the N domain, between residues 1 and 141. A conformational region of the epitope was also identified, including the residues around the glycan attached to Asn117, which explains the sensitivity to changes in glycosylation state, and another stretch localized around the motif 454TPPSRYN460. Site-directed mutagensis and inhibition assays revealed that mAb 5F1 inhibits ACE activity at high concentrations due to binding of residues on both sides of the active site cleft, thus supporting a hinge-bending mechanism for substrate binding of ACE.

Original languageEnglish (US)
Pages (from-to)9019-9031
Number of pages13
JournalBiochemistry
Volume46
Issue number31
DOIs
StatePublished - Aug 7 2007

Fingerprint

Epitope Mapping
Peptidyl-Dipeptidase A
Epitopes
Monoclonal Antibodies
Glycosylation
Western Blotting
Glucosidases
Mutagenesis
Bacteriophages
Neuraminidase
Hinges
Site-Directed Mutagenesis
Paraffin
Primates
Polysaccharides
Assays
Catalytic Domain
Screening
Display devices
Carbohydrates

ASJC Scopus subject areas

  • Biochemistry

Cite this

Danilov, S. M., Watermeyer, J. M., Balyasnikova, I. V., Gordon, K., Kugaevskaya, E. V., Elisseeva, Y. E., ... Sturrock, E. D. (2007). Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme. Biochemistry, 46(31), 9019-9031. https://doi.org/10.1021/bi700489v
Danilov, Sergei M. ; Watermeyer, Jean M. ; Balyasnikova, Irina V. ; Gordon, Kerry ; Kugaevskaya, Elena V. ; Elisseeva, Yulia E. ; Albrecht, Ronald F. ; Sturrock, Edward D. / Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme. In: Biochemistry. 2007 ; Vol. 46, No. 31. pp. 9019-9031.
@article{ab9eac5546a540f7914016c706890e7d,
title = "Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme",
abstract = "Angiotensin I-converting enzyme (ACE, peptidyl dipeptidase, EC 3.4.15.2) is a key enzyme in cardiovascular pathophysiology. A wide spectrum of monoclonal antibodies to different epitopes on the N and C domains of human ACE has been used to study different aspects of ACE biology. In this study we characterized the monoclonal antibody (mAb) 5F1, developed against the N domain of human ACE, which recognizes both the catalytically active and the denatured forms of ACE. The epitope for mAb 5F1 was defined using species cross-reactivity, synthetic peptide (PepScan technology) and phage display library screening, Western blotting, site-directed mutagenesis, and protein modeling. The epitope for mAb 5F1 shows no overlap with the epitopes of seven other mAbs to the N domain described previously and is localized on the other side of the N domain globule. The binding of mAb 5F1 to ACE is carbohydrate-dependent and increased significantly as a result of altered glycosylation after treatment with α-glucosidase-1 inhibitor, N-butyldeoxynojirimycin (NB-DNJ), or neuraminidase. Out of 17 species tested, mAb 5F1 showed strict primate ACE specificity. In addition, mAb 5F1 recognized human ACE in Western blots and on paraffin-embedded sections. The sequential part of the epitope for mAb 5F1 is created by the N-terminal part of the N domain, between residues 1 and 141. A conformational region of the epitope was also identified, including the residues around the glycan attached to Asn117, which explains the sensitivity to changes in glycosylation state, and another stretch localized around the motif 454TPPSRYN460. Site-directed mutagensis and inhibition assays revealed that mAb 5F1 inhibits ACE activity at high concentrations due to binding of residues on both sides of the active site cleft, thus supporting a hinge-bending mechanism for substrate binding of ACE.",
author = "Danilov, {Sergei M.} and Watermeyer, {Jean M.} and Balyasnikova, {Irina V.} and Kerry Gordon and Kugaevskaya, {Elena V.} and Elisseeva, {Yulia E.} and Albrecht, {Ronald F.} and Sturrock, {Edward D.}",
year = "2007",
month = "8",
day = "7",
doi = "10.1021/bi700489v",
language = "English (US)",
volume = "46",
pages = "9019--9031",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "31",

}

Danilov, SM, Watermeyer, JM, Balyasnikova, IV, Gordon, K, Kugaevskaya, EV, Elisseeva, YE, Albrecht, RF & Sturrock, ED 2007, 'Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme', Biochemistry, vol. 46, no. 31, pp. 9019-9031. https://doi.org/10.1021/bi700489v

Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme. / Danilov, Sergei M.; Watermeyer, Jean M.; Balyasnikova, Irina V.; Gordon, Kerry; Kugaevskaya, Elena V.; Elisseeva, Yulia E.; Albrecht, Ronald F.; Sturrock, Edward D.

In: Biochemistry, Vol. 46, No. 31, 07.08.2007, p. 9019-9031.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme

AU - Danilov, Sergei M.

AU - Watermeyer, Jean M.

AU - Balyasnikova, Irina V.

AU - Gordon, Kerry

AU - Kugaevskaya, Elena V.

AU - Elisseeva, Yulia E.

AU - Albrecht, Ronald F.

AU - Sturrock, Edward D.

PY - 2007/8/7

Y1 - 2007/8/7

N2 - Angiotensin I-converting enzyme (ACE, peptidyl dipeptidase, EC 3.4.15.2) is a key enzyme in cardiovascular pathophysiology. A wide spectrum of monoclonal antibodies to different epitopes on the N and C domains of human ACE has been used to study different aspects of ACE biology. In this study we characterized the monoclonal antibody (mAb) 5F1, developed against the N domain of human ACE, which recognizes both the catalytically active and the denatured forms of ACE. The epitope for mAb 5F1 was defined using species cross-reactivity, synthetic peptide (PepScan technology) and phage display library screening, Western blotting, site-directed mutagenesis, and protein modeling. The epitope for mAb 5F1 shows no overlap with the epitopes of seven other mAbs to the N domain described previously and is localized on the other side of the N domain globule. The binding of mAb 5F1 to ACE is carbohydrate-dependent and increased significantly as a result of altered glycosylation after treatment with α-glucosidase-1 inhibitor, N-butyldeoxynojirimycin (NB-DNJ), or neuraminidase. Out of 17 species tested, mAb 5F1 showed strict primate ACE specificity. In addition, mAb 5F1 recognized human ACE in Western blots and on paraffin-embedded sections. The sequential part of the epitope for mAb 5F1 is created by the N-terminal part of the N domain, between residues 1 and 141. A conformational region of the epitope was also identified, including the residues around the glycan attached to Asn117, which explains the sensitivity to changes in glycosylation state, and another stretch localized around the motif 454TPPSRYN460. Site-directed mutagensis and inhibition assays revealed that mAb 5F1 inhibits ACE activity at high concentrations due to binding of residues on both sides of the active site cleft, thus supporting a hinge-bending mechanism for substrate binding of ACE.

AB - Angiotensin I-converting enzyme (ACE, peptidyl dipeptidase, EC 3.4.15.2) is a key enzyme in cardiovascular pathophysiology. A wide spectrum of monoclonal antibodies to different epitopes on the N and C domains of human ACE has been used to study different aspects of ACE biology. In this study we characterized the monoclonal antibody (mAb) 5F1, developed against the N domain of human ACE, which recognizes both the catalytically active and the denatured forms of ACE. The epitope for mAb 5F1 was defined using species cross-reactivity, synthetic peptide (PepScan technology) and phage display library screening, Western blotting, site-directed mutagenesis, and protein modeling. The epitope for mAb 5F1 shows no overlap with the epitopes of seven other mAbs to the N domain described previously and is localized on the other side of the N domain globule. The binding of mAb 5F1 to ACE is carbohydrate-dependent and increased significantly as a result of altered glycosylation after treatment with α-glucosidase-1 inhibitor, N-butyldeoxynojirimycin (NB-DNJ), or neuraminidase. Out of 17 species tested, mAb 5F1 showed strict primate ACE specificity. In addition, mAb 5F1 recognized human ACE in Western blots and on paraffin-embedded sections. The sequential part of the epitope for mAb 5F1 is created by the N-terminal part of the N domain, between residues 1 and 141. A conformational region of the epitope was also identified, including the residues around the glycan attached to Asn117, which explains the sensitivity to changes in glycosylation state, and another stretch localized around the motif 454TPPSRYN460. Site-directed mutagensis and inhibition assays revealed that mAb 5F1 inhibits ACE activity at high concentrations due to binding of residues on both sides of the active site cleft, thus supporting a hinge-bending mechanism for substrate binding of ACE.

UR - http://www.scopus.com/inward/record.url?scp=34547728057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547728057&partnerID=8YFLogxK

U2 - 10.1021/bi700489v

DO - 10.1021/bi700489v

M3 - Article

VL - 46

SP - 9019

EP - 9031

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 31

ER -